HRP20190860T1 - POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a - Google Patents
POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a Download PDFInfo
- Publication number
- HRP20190860T1 HRP20190860T1 HRP20190860TT HRP20190860T HRP20190860T1 HR P20190860 T1 HRP20190860 T1 HR P20190860T1 HR P20190860T T HRP20190860T T HR P20190860TT HR P20190860 T HRP20190860 T HR P20190860T HR P20190860 T1 HRP20190860 T1 HR P20190860T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- therapy
- pml
- vla
- jcv
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- 241000701460 JC polyomavirus Species 0.000 claims 9
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 238000002650 immunosuppressive therapy Methods 0.000 claims 6
- 229960005027 natalizumab Drugs 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 229960002170 azathioprine Drugs 0.000 claims 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 3
- 229960001156 mitoxantrone Drugs 0.000 claims 3
- 229940014456 mycophenolate Drugs 0.000 claims 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 2
- 206010051290 Central nervous system lesion Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Exhaust Gas After Treatment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Claims (7)
1. Postupak procjene pacijentovog rizika od razvijanja progresivne multifokalne leukoencefalopatije (PML), postupak sadrži:
određivanje titra antitijela JC Virusa (JCV), izraženo kao vrijednost indeksa u uzorku seruma ili plazme pacijenta pri čemu je za pacijenta ustanovljeno da ima visok rizik ako je određena vrijednost indeksa JCV antitijela >1,5;
pri čemu se vrijednost indeksa određuje normaliziranjem OD vrijednosti uzorka prema odreznom kalibratoru, pri čemu je odrezni kalibrator prilagođen kako bi imao OD vrijednost od 1, pri čemu odrezni kalibrator sadrži smjesu seruma pozitivnog na JCV antitijela i seruma negativnog na JCV antitijela,
pri čemu normaliziranje OD vrijednosti negativne kontrole koja sadrži serum negativan na JCV antitijela prema odreznom kalibratoru rezultira vrijednošću indeksa od 0,1, i
pri čemu je titar JCV antitijela određen ELISA testom kako bi se detektirala JCV antitijela u uzorku.
2. Postupak prema zahtjevu 1, naznačen time što je titar JCV antitijela retestiran u 6-mjesečnim ili 12-mjesečnim intervalima, pri čemu povišenje u titru antitijela ili postotna inhibicija naznačuje povišenje pacijentovog rizika od razvijanja PML-a.
3. Postupak prema bilo kojem od zahtjeva 1-2, koji nadalje sadrži:
(a) određivanje je li pacijent primao liječenje natalizumabom duže od 24 mjeseca; i/ili
(b) određivanje je li pacijent primao specificiranu ne-anti-VLA-4 imunosupresijsku terapiju, pri čemu je specificirana ne-anti-VLA-4 imunosupresijska terapija odabrana od mitoksantrona, metotreksata, azatioprina, ciklofosfamida, mikofenolata, anti-CD20 terapije, anti-CD11a terapije i mikofenolat mofetila.
4. Postupak prema bilo kojem od zahtjeva 1-3, naznačen time što je pacijent klasificiran kao da ima viši rizik od PML-a ako je pacijent primao natalizumab duže od 24 mjeseca, te nije prethodno primao specificiranu ne-anti-VLA-4 imunosupresijsku terapiju, pri čemu je specificirana ne-anti-VLA-4 imunosupresijska terapija odabrana od mitoksantrona, metotreksata, azatioprina, ciklofosfamida, mikofenolata, anti-CD20 terapije, anti-CD11a terapije i mikofenolat mofetila.
5. Postupak prema bilo kojem od zahtjeva 1-4, koji nadalje sadrži praćenje pacijenata na razvoj PML-a, izborno pri čemu navedeno praćenje uključuje MRI skeniranje kako bi se identificirale lezije mozga.
6. Postupak procjenjivanja pacijentovog rizika od razvijanja PML-a prema zahtjevu 1, koji sadrži:
(a) određivanje je li razina anti-JCV antitijela veća od vrijednosti indeksa od 1,5;
(b) određivanje je li pacijent primao natalizumab duže od 24 mjeseca; i
(c) određivanje je li pacijent primao ne-anti-VLA-4 imunosupresijsku terapiju, pri čemu je ne-anti-VLA-4 imunosupresijska terapija odabrana od mitoksantrona, metotreksata, azatioprina, ciklofosfamida, mikofenolata, anti-CD20 terapije, anti-CD11a terapije i mikofenolat mofetila; te ovisno o rezultatima, procjenjivanje pacijentovog rizika od razvijanja PML-a.
7. Postupak prema zahtjevu 1, naznačen time što pacijent prima terapiju natalizumabom.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491810P | 2011-05-31 | 2011-05-31 | |
| US201161508584P | 2011-07-15 | 2011-07-15 | |
| US201161550257P | 2011-10-21 | 2011-10-21 | |
| US201261636588P | 2012-04-20 | 2012-04-20 | |
| PCT/US2012/040283 WO2012166971A2 (en) | 2011-05-31 | 2012-05-31 | Method of assessing risk of pml |
| EP12792375.3A EP2715352B1 (en) | 2011-05-31 | 2012-05-31 | Method of assessing risk of pml |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190860T1 true HRP20190860T1 (hr) | 2019-06-28 |
Family
ID=47260338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230186TT HRP20230186T1 (hr) | 2011-05-31 | 2012-05-31 | METODA PROCJENE RIZIKA OD PML-a |
| HRP20190860TT HRP20190860T1 (hr) | 2011-05-31 | 2019-05-09 | POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230186TT HRP20230186T1 (hr) | 2011-05-31 | 2012-05-31 | METODA PROCJENE RIZIKA OD PML-a |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20190227064A1 (hr) |
| EP (3) | EP4187248A1 (hr) |
| JP (5) | JP6243838B2 (hr) |
| KR (3) | KR102292563B1 (hr) |
| CN (1) | CN103635803A (hr) |
| AU (1) | AU2012262122B2 (hr) |
| CA (1) | CA2836490A1 (hr) |
| CY (1) | CY1121981T1 (hr) |
| DK (2) | DK2715352T3 (hr) |
| ES (2) | ES2939482T3 (hr) |
| FI (1) | FI3575792T3 (hr) |
| HR (2) | HRP20230186T1 (hr) |
| HU (2) | HUE061244T2 (hr) |
| LT (2) | LT2715352T (hr) |
| PL (2) | PL3575792T3 (hr) |
| PT (2) | PT3575792T (hr) |
| RS (2) | RS58967B1 (hr) |
| SI (2) | SI3575792T1 (hr) |
| WO (1) | WO2012166971A2 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
| MX2008011176A (es) | 2006-03-03 | 2008-09-10 | Elan Pharm Inc | Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab. |
| CA2776756A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
| IN2012DN06139A (hr) | 2010-01-11 | 2015-09-18 | Biogen Idec Inc | |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| WO2012166971A2 (en) | 2011-05-31 | 2012-12-06 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML |
| WO2015042254A1 (en) * | 2013-09-18 | 2015-03-26 | The Johns Hopkins University | Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk |
| EP3757224A3 (en) | 2014-02-27 | 2021-03-17 | Biogen MA Inc. | Method of assessing risk of pml |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| JP2021501152A (ja) | 2017-10-26 | 2021-01-14 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ナタリズマブの延長間隔投与 |
| IL302929A (en) | 2020-11-14 | 2023-07-01 | Biogen Ma Inc | Biphasic subcutaneous dosing regimens for anti-VLA-4 antibodies |
| EP4323407A1 (en) | 2021-04-13 | 2024-02-21 | Biogen MA Inc. | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
| WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| WO2006112951A2 (en) * | 2005-03-03 | 2006-10-26 | Seedlings Life Science Ventures, Llc | Method of risk management for patients undergoing natalizumab treatment |
| JP2009500040A (ja) * | 2005-07-08 | 2009-01-08 | フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン・デイー／ビー／エイ ドレクセルユニバーシテイカレツジオブメデイシン | ニューロンの神経炎症的破壊をモニタリングする方法およびホスホリパーゼａ２に関連する炎症性成分を有する疾患を処置する方法 |
| LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
| US20110184747A1 (en) * | 2006-08-09 | 2011-07-28 | Carmen Bozic | Method for distribution of a drug |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| JP5798926B2 (ja) * | 2008-11-07 | 2015-10-21 | シーケンタ インコーポレイテッド | 配列解析によって病態をモニターする方法 |
| IN2012DN06139A (hr) * | 2010-01-11 | 2015-09-18 | Biogen Idec Inc | |
| WO2012166971A2 (en) | 2011-05-31 | 2012-12-06 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML |
-
2012
- 2012-05-31 WO PCT/US2012/040283 patent/WO2012166971A2/en active Application Filing
- 2012-05-31 DK DK12792375.3T patent/DK2715352T3/da active
- 2012-05-31 KR KR1020197031074A patent/KR102292563B1/ko active IP Right Grant
- 2012-05-31 SI SI201232024T patent/SI3575792T1/sl unknown
- 2012-05-31 EP EP22209669.5A patent/EP4187248A1/en active Pending
- 2012-05-31 PT PT191694827T patent/PT3575792T/pt unknown
- 2012-05-31 PT PT12792375T patent/PT2715352T/pt unknown
- 2012-05-31 JP JP2014513712A patent/JP6243838B2/ja active Active
- 2012-05-31 PL PL19169482.7T patent/PL3575792T3/pl unknown
- 2012-05-31 PL PL12792375T patent/PL2715352T3/pl unknown
- 2012-05-31 CA CA2836490A patent/CA2836490A1/en active Pending
- 2012-05-31 ES ES19169482T patent/ES2939482T3/es active Active
- 2012-05-31 AU AU2012262122A patent/AU2012262122B2/en active Active
- 2012-05-31 FI FIEP19169482.7T patent/FI3575792T3/fi active
- 2012-05-31 EP EP19169482.7A patent/EP3575792B1/en active Active
- 2012-05-31 KR KR1020137031996A patent/KR102039751B1/ko active IP Right Grant
- 2012-05-31 LT LTEP12792375.3T patent/LT2715352T/lt unknown
- 2012-05-31 KR KR1020217026042A patent/KR102473834B1/ko active IP Right Grant
- 2012-05-31 ES ES12792375T patent/ES2729945T3/es active Active
- 2012-05-31 DK DK19169482.7T patent/DK3575792T3/da active
- 2012-05-31 RS RS20190690A patent/RS58967B1/sr unknown
- 2012-05-31 HU HUE19169482A patent/HUE061244T2/hu unknown
- 2012-05-31 SI SI201231596T patent/SI2715352T1/sl unknown
- 2012-05-31 RS RS20230142A patent/RS63989B1/sr unknown
- 2012-05-31 HU HUE12792375A patent/HUE043339T2/hu unknown
- 2012-05-31 CN CN201280026045.5A patent/CN103635803A/zh active Pending
- 2012-05-31 EP EP12792375.3A patent/EP2715352B1/en not_active Revoked
- 2012-05-31 LT LTEP19169482.7T patent/LT3575792T/lt unknown
- 2012-05-31 HR HRP20230186TT patent/HRP20230186T1/hr unknown
-
2017
- 2017-07-26 JP JP2017144730A patent/JP6663396B2/ja active Active
-
2018
- 2018-12-05 US US16/211,154 patent/US20190227064A1/en not_active Abandoned
-
2019
- 2019-05-09 HR HRP20190860TT patent/HRP20190860T1/hr unknown
- 2019-06-03 CY CY20191100584T patent/CY1121981T1/el unknown
-
2020
- 2020-02-14 JP JP2020023062A patent/JP7128221B2/ja active Active
-
2021
- 2021-08-03 US US17/393,335 patent/US20220011310A1/en active Pending
- 2021-10-13 JP JP2021168084A patent/JP7353338B2/ja active Active
-
2023
- 2023-09-19 JP JP2023151467A patent/JP2023169307A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190860T1 (hr) | POSTUPAK PROCJENJIVANJA RIZIKA OD PML-a | |
| HRP20221390T1 (hr) | Analiza za antitijela jc virusa | |
| Zhang et al. | A comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome | |
| JP2014518377A5 (hr) | ||
| BR112012030788A2 (pt) | métodos de detecção de anticorpos monoclonais para enzimas que conferem resistência ao ácido 2,4-diclorofenoxiacético em plantas | |
| MX366275B (es) | Metodos para detectar y medir la agregacion. | |
| RU2018111431A (ru) | Новые способы и наборы для обнаружения нарушений цикла мочевины с помошью масс-спектрометрии | |
| JP2013516633A5 (hr) | ||
| JP2016507066A5 (hr) | ||
| RU2015125739A (ru) | Тесты детекции нейтрализующих аутоантител для биологической терапии | |
| WO2012099884A8 (en) | Methods for amplification and detection of prions | |
| HRP20220538T1 (hr) | Uređaj za detekciju krevetnih stjenica | |
| Kumar et al. | Antibodies to m‐type phospholipase A2 receptor in children with idiopathic membranous nephropathy | |
| HRP20171623T1 (hr) | Poboljšana cjepivna dijagnostika | |
| ZA202002415B (en) | Detection of symmetrical dimethylarginine | |
| Chen et al. | Diagnostic value of serum Epstein-Barr virus capsid antigen-IgA for nasopharyngeal carcinoma: a meta-analysis based on 21 studies | |
| Lin et al. | An UHPLC–MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction | |
| JP2016520846A5 (hr) | ||
| Jiang et al. | Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients | |
| Mravinacova et al. | A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies | |
| Salazar et al. | Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis | |
| Fialova et al. | Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum | |
| Sharnez et al. | Methodology for assessing product inactivation during cleaning Part I: experimental approach and analytical methods | |
| Reed et al. | Novel mass spectrometry based detection and identification of variants of rabies virus nucleoprotein in infected brain tissues | |
| JP2018528439A5 (hr) |